Form 4: Quest Diagnostics SVP Karthik Kuppusamy Reports Stock Transactions
SEC Form 4 Filing
SVP of Clinical Solutions at Quest Diagnostics, Karthik Kuppusamy, reports acquisition and disposal of company stock, including dividend reinvestment and stock purchase plan transactions.
Summary
- Karthik Kuppusamy, SVP of Clinical Solutions at Quest Diagnostics, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
- On October 21, 2024, Kuppusamy acquired 21 shares of common stock at $149.37 per share through a dividend reinvestment plan.
- Kuppusamy also reported the disposal of 11,509 shares of common stock.
- The report indicates beneficial ownership of 358 shares held by a trust and 1,565 shares held in a 401(k) plan.
- The filing includes shares acquired through the company's stock purchase plan since the last Form 4 filing.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard SEC filing reporting stock transactions. There's no inherent positive or negative implication.
Industry Context
This filing is a routine disclosure required by the SEC for corporate insiders, providing transparency to investors regarding the trading activities of company executives.
Stakeholder Impact
- The filing provides transparency to shareholders regarding insider trading activity.
- It assures stakeholders that executives are adhering to SEC regulations.
Key Dates
| Date | Description |
|---|---|
| 10/21/2024 | Date of common stock transaction (acquisition of 21 shares). |
| 10/25/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.